OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic ...
SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initia ...
WEST LAFAYETTE, Ind. — Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will ...
SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound ...
Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease. The study ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
BriaCell (BCTX) Therapeutics presents positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium, SABCS, taking place December ...
Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month "Obesity is a complex condition, and no single treatment works for everyone.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results